Ivosidenib (IVO) is an inhibitor of IDH1 R132 that acts in synergy with AZA inducing myeloid blast differentiation [52,53], with promising results of this combination in the clinical scenario for relapsed/refractory (R/R) AML [54]. Here, IDH1 is linked to acute myeloid leukemia.